
    
      A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the
      Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus
      Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
      who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab
      by HER2 Status (SAGE)
    
  